Member Info for Chuggley

Tony. That shift pattern will still deliver 2 million a week manufacturing capacity. Just a tad more than at the start 100k prr week. When we were all first here and they talked of 500k per week we saw £2-3 per share as realistic. Now we are aiming at 4 x that capacity. I don't think there is no reason for this .... and if we do then need to up to 24/7. Well simple maths .....

Most of us have filtered him. He just talks to himself

And there is no other antibody lft with mrha anyway. So we must have a more than average chance. Accurate. Specific. Cheap. British

Maybe. Maybe not. But this tender clearly states ce or mrha

Surely if they expect delivery to commence in February this needs awarding this month ?

Trevor. Reported

If this is another pair of home knited socks ill blimin scream

I completely understand supplying the UK government contract first. But they've only ordered 1m. And surely that was filled weeks ago. In absence of any orders surely we market the product and sell it to whoever orders. Or are we manufacturing for a bigger order thats not been announced yet?

Brightly - i cant take the credit - its a copy of MBs post - but i concur 100%

Bumping MBs comment up
2m tests per week is for Antigen, ABC-19 and cd4. £2 per test average is conversation. The food tests are on top of that made in Cambridge, plus any Elisa sales they manage plus the lab testing service they are launching.

If all goes to plan, which I believe in current circumstances is a easily achievable plan, I can see a minimum of £240m profit per year. £240m at a prudent 5x multiplier divide by 180m shares.

Personally I see growth beyond 2m lateral flow tests per week. I also see a huge cash balance that they can either invest, pay dividends or share buy backs. That’s why I also think a 5x multiplier is prudent.

I bet their were similar forecasts for NCYT saying it couldn’t get to £6. The simple fact is 2m tests per week from April onwards will be made. The likelihood is they will achieve minimum 3-5 years traction on those sales based on previous infectious diseases. I don’t often talk about share price but this is the maths based on the business plan Omega have delivered.

Risk factors:

COVID goes away overnight - check the history of infectious diseases. They take decades to eradicate if it can ever be achieved at all.

No sales take up.... desperate need for lateral flow tests. The more made the more they can be rolled out in different social environments. Any quality test made will be bought

Antigen test fails - Mologic are world class I back them over other developers any day. Make more antibody tests

Antibody test not taken up - make more antigen tests.

Both products fail- market capacity to the most in demand tests.

Colin has put a plan together at a level that is achievable with the cash raise at low risk to cash flow, and high probability of 100% utilisation. I get the impression they did not want to build capacity they cannot guarantee 100% utilisation for the next few years.

This will be very rewarding to watch this play out over the next 6-12 months. Party has not even started yet. The lateral flow market has hardly been launched. Omega are very well placed to take advantage.

Based on that MB and being Conservative with only 1m tests pw so only 50 % of capacity come April. We could look at over £3 a share.

Good for you. We all need to make our own judgement and yes profit is good. I'm just a couple of pence per share down. I've been here since late April... but I remain confident although a little stressed. This is still going places. Sentiment may be a bit thin at the moment. But that will change. Testings going no where. But demand is increasing beyond supply

So do we all. But these things haven't changed.

I'm posting your post again korda. Just to remind us all when feeling down ....
· Food intolerance business showing early signs of H2 recovery and significant growth opportunity in China

· VISITECT® CD4 Advanced Disease is the world’s only point-of-care instrument free test for monitoring people living with HIV

· CHAI is driving early country implementation and WHO prequalification enables NGO funding support for long-term use

· Exciting opportunity for the commercial roll-out of the AbC-19™ Rapid test to the UK Government and other customers

· MHRA approval for self-test use of the AbC-19™ Rapid test expected following final usability study

· Production of AbC-19™ Rapid test from the Alva site is now well underway with shipments to Abingdon already commenced

· Exciting opportunities for commercial launch of Mologic antigen test as we expect antigen testing to remain a key tool in controlling COVID-19 in 2021 and beyond

· Targeted production capacity of 500,000 lateral flow tests a week by the end of December remains on schedule

News would make their ipo more attractive and possibly more valuable
But please let's not forget this is only one element of what omega should offer. Let's not ignore mologic antigen test in TT. this will I hope complete in 2 weeks ish.
And I'm as frustrated as the rest of you

Must say I'm very confident still. But as to my patience??? Lol. That's a bit thinner than last week. Unlike my belly after just eating a huge beef stew

Must say I'm very confident still. But as to my patience??? Lol. That's a bit thinner than last week. Unlike my belly after just eating a huge beef stew

As usual. Looks like lots of buys being marked as sells

Just looked at your past posts lol. Go away or shall we all pop over to MERC and talk complete rubbish

It is a lab test. Return sample to lab. Results available after a day or two